Literature DB >> 18599281

HMGB1: a two-headed signal regulating tumor progression and immunity.

Lara Campana1, Lidia Bosurgi, Patrizia Rovere-Querini.   

Abstract

Cells of the innate immune system sense tissue damage recognizing in the extracellular environment bona fide intracellular moieties, like high mobility group box 1 (HMGB1). In the case of tumors, HMGB1 recognition has a paradoxical dual effect: it promotes tumor neoangiogenesis and triggers protective anti-neoplastic T-cell responses. Recent advances in the study of HMGB1 have identified candidate molecular mechanisms underlying these apparently contrasting outcomes. A surprising role for innate receptors, including toll like receptor 4 (TLR4), in the response to conventional cancer radio and chemotherapy has also recently emerged, providing new insight into the mechanisms by which these treatments actually work.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18599281     DOI: 10.1016/j.coi.2008.04.012

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  52 in total

Review 1.  Role of TLR2-dependent inflammation in metastatic progression.

Authors:  Sunhwa Kim; Michael Karin
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

2.  HMGB1 promotes lymphangiogenesis of human lymphatic endothelial cells in vitro.

Authors:  Yuanyuan Qiu; Ying Chen; Xin Fu; Lei Zhang; Jing Tian; Quan Hao
Journal:  Med Oncol       Date:  2010-12-22       Impact factor: 3.064

Review 3.  Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer.

Authors:  Geetha Srikrishna; Hudson H Freeze
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

4.  High-mobility group box 1 released by autophagic cancer-associated fibroblasts maintains the stemness of luminal breast cancer cells.

Authors:  Xi-Long Zhao; Yong Lin; Jun Jiang; Zhuo Tang; Shuai Yang; Lu Lu; Yan Liang; Xue Liu; Jiao Tan; Xu-Gang Hu; Qin Niu; Wen-Juan Fu; Ze-Xuan Yan; De-Yu Guo; Yi-Fang Ping; Ji Ming Wang; Xia Zhang; Hsiang-Fu Kung; Xiu-Wu Bian; Xiao-Hong Yao
Journal:  J Pathol       Date:  2017-09-21       Impact factor: 7.996

5.  Altered local and systemic immune profiles underlie lymph node metastasis in breast cancer patients.

Authors:  Neta S Zuckerman; Hongxiang Yu; Diana L Simons; Nupur Bhattacharya; Valeria Carcamo-Cavazos; Ning Yan; Frederick M Dirbas; Denise L Johnson; Erich J Schwartz; Peter P Lee
Journal:  Int J Cancer       Date:  2012-11-26       Impact factor: 7.396

Review 6.  Alarmins: awaiting a clinical response.

Authors:  James K Chan; Johannes Roth; Joost J Oppenheim; Kevin J Tracey; Thomas Vogl; Marc Feldmann; Nicole Horwood; Jagdeep Nanchahal
Journal:  J Clin Invest       Date:  2012-08-01       Impact factor: 14.808

Review 7.  Skewed Signaling through the Receptor for Advanced Glycation End-Products Alters the Proinflammatory Profile of Tumor-Associated Macrophages.

Authors:  Armando Rojas; Paulina Araya; Jacqueline Romero; Fernando Delgado-López; Ileana Gonzalez; Carolina Añazco; Ramon Perez-Castro
Journal:  Cancer Microenviron       Date:  2018-08-08

8.  Antitumor immunity induced after α irradiation.

Authors:  Jean-Baptiste Gorin; Jérémie Ménager; Sébastien Gouard; Catherine Maurel; Yannick Guilloux; Alain Faivre-Chauvet; Alfred Morgenstern; Frank Bruchertseifer; Michel Chérel; François Davodeau; Joëlle Gaschet
Journal:  Neoplasia       Date:  2014-04       Impact factor: 5.715

Review 9.  The receptor for advanced glycation end products (RAGE) and the lung.

Authors:  Stephen T Buckley; Carsten Ehrhardt
Journal:  J Biomed Biotechnol       Date:  2010-01-19

10.  Life after death: targeting high mobility group box 1 in emergent cancer therapies.

Authors:  Z Sheng Guo; Zuqiang Liu; David L Bartlett; Daolin Tang; Michael T Lotze
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.